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aBStract
Pseudomonas aeruginosa has been determined to be the distinct cause of a number of different infections 
in both humans and animals. Apart from its high intrinsic resistance, which makes it difficult to treat, it also has 
a great capacity to acquire further resistance mechanisms. these mechanisms can be present simultaneously 
in one cell, conferring a multiresistant phenotype. taking into account that the known risk factor for selection 
of resistant strains is excessive and inappropriate drug use, especially fluoroquinolones, the aim of this study 
was to determine the susceptibility of P. aeruginosa isolates to these antibacterial agents. the susceptibility 
of 90 canine isolates was determined by disk diffusion susceptibility test and the broth microdilution method. 
Both methods showed that isolates were significantly more sensitive to ciprofloxacin than to marbofloxacin or 
enrofloxacin, and more sensitive to marbofloxacin than to enrofloxacin. The results of microdilution and disk 
diffusion testing were in 98.9% agreement for ciprofloxacin and in 91.1% agreement for marbofloxacin, with no 
statistically significant difference between the two methods (P>0.05) for these two antibiotics. For enrofloxacin, 
the results of microdilution and disk diffusion testing were in 76.6% agreement, with a statistically significant 
disagreement between the two methods (P<0.05). In 16 cases, the disk diffusion test overestimated the number 
of strains susceptible to enrofloxacin compared with the microdilution test. These results suggest that for P. 
aeruginosa infections in dogs, therapy using enrofloxacin, based on the results of disk diffusion testing, may 
lead to ineffective treatment and could contribute to selection of resistant and multiresistant strains. 
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Introduction 
Pseudomonas aeruginosa causes opportunistic infections in both humans and 
animals. In dogs, this bacterium has been recognized as the distinct cause of infections 
such as: otitis externa, urinary tract infections, conjunctivitis, pneumonia, endocarditis 
and dermatitis (MARKEY et al., 2013). 
treatment of P. aeruginosa infections is difficult because of its high intrinsic 
resistance to many commonly used antibiotics, such as penicillins, first and second 
generation cephalosporins, macrolides and chloramphenicol, some aminoglycosides, 
some fluoroquinolones, tetracyclines and sulfonamides (LIVERMORE et al., 2001). 
therefore, the choice of antibiotics that can be used to treat P. aeruginosa infections 
is very narrow, especially in veterinary medicine (GIGUÈRE et al., 2013). Furthermore, 
apart from its high intrinsic resistance, P. aeruginosa also has a great capacity to acquire 
further resistance mechanisms, which include: efflux pump expression, decreased 
permeability, target site alterations and production of antibiotic-hydrolyzing enzymes. 
these mechanisms can be present simultaneously in one cell, conferring a multiresistant 
phenotype. treatment of infections caused by such microorganisms is very challenging 
(STRATEVA and YORDANOV, 2009). 
the known risk factors for selection of resistant and multiresistant strains are 
excessive drug use and inappropriate dosage regimens without previous antimicrobial 
susceptibility testing. This is especially true for fluoroquinolones as they are known as 
antimicrobials with a high tendency to select resistant bacteria if dosed inappropriately 
(GIGUÈRE et al., 2013). 
a precise dose of a certain antimicrobial required to inhibit growth of a 
pathogen is determined on the basis of the minimum inhibitory concentration (MIC). 
according to recommendations by the Clinical and Laboratory Standards Institute 
(CLSI), P. aeruginosa isolates with enrofloxacin MIC of ≤0.5 μg/mL are reported as 
susceptible, while intermediately susceptible strains have MICs between 1 and 2 μg/mL 
(ANONYMOUS, 2013b). however, COLE et al. (2008) state that enrofloxacin should be 
dosed at 20 mg/kg once a day (high end of the enrofloxacin dose range) for the treatment 
of infections caused by bacteria with a MIC of 0.51-0.64 μg/mL. Considering this, all 
P. aeruginosa isolates estimated as intermediately susceptible to enrofloxacin should be 
reported as resistant. Besides, without information about the MIC, clinicians cannot make 
an appropriate decision about the dosage regimen. In the bacteriological laboratory of 
the Faculty of Veterinary Medicine in Croatia disk diffusion is the method routinely used 
for susceptibility testing, and the question is whether this method is accurate enough to 
achieve appropriate therapeutic results if maximum doses of enrofloxacin are used for all 
P. aeruginosa strains estimated as susceptible. 
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the aim of this study was to determine the susceptibility of P. aeruginosa to 
enrofloxacin and marbofloxacin as fluoroquinolones registered for use in veterinary 
medicine in Croatia, and susceptibility to ciprofloxacin, which is frequently used off-label 
in veterinary medicine. Further, our goal was to evaluate the validity of reporting results 
of disk diffusion testing for chosen fluoroquinolones. 
Materials and methods
Ninety P. aeruginosa strains isolated from dogs in the bacteriological laboratory 
at the Department for Microbiology and Infectious Diseases with Clinic of the Faculty 
of Veterinary Medicine, University of Zagreb, in the period from December 2008 to 
December 2009, were used in this study. The majority of isolates were recovered from 
the ear canal (62.2%) and skin (13.3%). the rest were obtained from the throat (5.6%), 
nostrils (4.5%), conjunctival sac (4.5%), vagina (3.3%), anal sac (2.2%), foreskin (1.1%), 
bone fracture (1.1%), urine (1.1%) and feces (1.1%). Identification of P. aeruginosa was 
carried out according to the procedure described by MARKEY et al. (2013). antimicrobial 
susceptibility to enrofloxacin, marbofloxacin and ciprofloxacin was determined by the 
disk diffusion and broth microdilution methods, according to the CLSI recommendations 
(ANONYMOUS, 2013a). Both susceptibility tests were performed from the same bacterial 
inoculum, adjusted to turbidity of 0.5 McFarland. The antimicrobial concentration range 
for microdilution testing was 0.25 to 256 μg/mL for enrofloxacin (Krka, Slovenia), 
0.125 to 128 μg/mL for marbofloxacin (Vétoquinol, France) and 0.06 to 64 μg/mL for 
ciprofloxacin (Salutas Pharma GmbH, Germany). Disk diffusion testing was performed 
with 5 μg disks of enrofloxacin (Bio-Rad, USA), marbofloxacin (Bio-Rad, USA) and 
ciprofloxacin (bioMerieux, France).
Inhibition zone diameters and minimum inhibitory concentrations were interpreted 
according to the criteria recommended by the CLSI in documents Vet01-S2 and 
M100-S24, and they are summarized in Tables 1 and 2 (ANONYMOUS, 2013b; 
ANONYMOUS, 2014). Pseudomonas aeruginosa atCC 27853 was included in the study 
as a control strain. 
Statistical analysis was performed using Statistica v12.5. Software (StatSoft Inc.). 
Basic data processing was performed by standard procedures of descriptive statistics. 
Significance of differences between the three fluoroquinolones was determined by the 
Wilcoxon matched pairs test, with statistical significance set at P<0.05. The differences 
between the two methods were analyzed using separate Wilcoxon matched pairs tests 
for each antibiotic included in the research. According to CLSI document M37-A3, 
discrepancy rates were classified into three categories: very major discrepancy (false-
susceptible disk diffusion test result), major discrepancy (false-resistant disk diffusion test 
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result) and minor discrepancy (difference in one interpretation category) (ANONYMOUS, 
2008). 
Results
Disk diffusion antimicrobial susceptibility testing showed that among the tested 
fluoroquinolones, ciprofloxacin was the most active compound, with 95.6% sensitive 
strains. The least active was enrofloxacin, with 25 (27.8%) susceptible and 50 (55.6%) 
intermediately susceptible isolates. the results of disk diffusion testing and the criteria used 
for interpretation of inhibition zone diameters are summarized in Table 1. Distributions of 
inhibition zone diameters for each tested fluoroquinolone are summarized in Fig 1. 
Table 1. Zone diameter interpretation standards and results of disk diffusion testing for 90 
Pseudomonas aeruginosa isolates
Disk diffusion testing
zone diameter breakpoints (mm) results of disk diffusion testing
antimicrobial 







Enrofloxacin 23 17-22 16 25 (27.8) 50 (55.6) 15 (16.7)
Marbofloxacin 20 15-19 14 78 (86.7) 7 (7.8) 5 (5.6)
Ciprofloxacin 21 16-20 15 86 (95.6) 2 (2.2) 2 (2.2)
S = susceptible, I = intermediately susceptible, r = resistant
Table 2. MIC Interpretive Standards and results of microdilution testing for 90 Pseudomonas 
aeruginosa isolates
MIC breakpoints 
(μg/mL) results of microdilution testing
antimicrobial 






strains (%) MIC50 MIC90
Enrofloxacin 0.5 1-2 4 8 (8.9) 68 (75.6) 14 (15.6) 1 4
Marbofloxacin 1 2 4 73 (81.1) 9 (10.0) 8 (8.9) 1 2
Ciprofloxacin 1 2 4 85 (94.4) 3 (3.3) 2 (2.2) 0.25 0.5
MIC = minimum inhibitory concentration, MIC50 = MIC that inhibited at least 50% of the isolates, MIC90 = MIC 
that inhibited at least 90% of the isolates. S = susceptible, I = intermediately susceptible, r = resistant
From the results of disk diffusion testing, isolates were significantly more sensitive 
to ciprofloxacin than to marbofloxacin or enrofloxacin (P<0.05). Furthermore, the isolates 
were significantly more susceptible to marbofloxacin than to enrofloxacin (P<0.05). 
From the results of microdilution testing, the isolates were also significantly 
more susceptible to ciprofloxacin than to marbofloxacin or enrofloxacin (P<0.05) and 
were significantly more susceptible to marbofloxacin than to enrofloxacin (P<0.05). 
There were 85 strains (94.4%) sensitive to ciprofloxacin with MICs between 0.06 and 
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1 μg/mL. Seventy-three strains (81.1%) showed susceptibility to marbofloxacin, with 
slightly higher MICs, mostly between 0.25 and 1 μg/mL. With eight (8.9%) susceptible 
strains, enrofloxacin was the least active compound. The antimicrobial activities of the 
three fluoroquinolones against P. aeruginosa strains and their MIC50 and MIC90 values 
are summarized in Table 2. Distributions of MICs for each tested fluoroquinolone are 
summarized in Fig, 1.
Fig. 1. Scattergrams of enrofloxacin (a), marbofloxacin (b) and ciprofloxacin (c) MICs versus 
disk diffusion zone diameters for 90 Pseudomonas aeruginosa isolates. Numbers represent 
the numbers of isolates. The horizontal and vertical lines represent MIC and disk diffusion 
breakpoints, respectively.
For ciprofloxacin, the results of microdilution and disk diffusion testing were in 
98.9% agreement, with no statistically significant disagreement between the two methods 
(P>0.05). There was only one minor error with one strain showing susceptibility on disk 
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There was no statistically significant disagreement between the results of the two 
methods for marbofloxacin, and the results were in 91.1% agreement. This comparison 
showed six minor errors and two very major errors. 
For enrofloxacin, the results of microdilution and disk diffusion testing were in 
76.6% agreement (69 isolates showed the same result by both methods) with a statistically 
significant disagreement between the two methods (P<0.05). Comparison identified 20 
(22.2%) minor errors and one (1.1%) very major error (Fig. 1). 
Discussion
In this study we carried out a comparison of the results obtained by two methods, 
disk diffusion and microdilution susceptibility testing. there were no statistically 
significant differences between those two methods for marbofloxacin and ciprofloxacin. 
On the other hand, comparison showed a statistically significant disagreement between 
the results obtained with microdilution and disk diffusion testing for enrofloxacin. Only 
76.6% of results were in agreement, and most of the disagreements were due to the disk 
diffusion test overestimating the number of susceptible strains compared to microdilution 
testing. Out of 20 minor errors, 16 errors were isolates estimated as susceptible by the 
disk diffusion method but intermediately susceptible by microdilution. Similar results 
were found by McKAY et al. (2007), where 87% agreement between microdilution and 
disk diffusion testing was reported for marbofloxacin, with no statistically significant 
disagreement between the two methods. For enrofloxacin, authors reported that the 
results of the two methods were in 74% agreement, with a statistically significant 
difference between them. In 20 instances, disk diffusion testing overestimated the 
number of enrofloxacin-susceptible strains compared with microdilution. On the basis 
of these results, the authors concluded that the use of disk diffusion testing to evaluate 
the enrofloxacin susceptibility of P. aeruginosa strains may result in inappropriate and 
ineffective therapy (McKAY et al., 2007). according to COLE et al. (2008), for bacteria with 
a minimum inhibitory concentration of 0.51-0.64 μg/mL, enrofloxacin should be dosed 
at 20 mg/kg (high end of the enrofloxacin dose range). On this basis, all intermediately 
susceptible isolates should be considered resistant, since appropriate tissue levels cannot 
be obtained even with a maximum dose of enrofloxacin. On the basis of the results of 
disk diffusion testing, it is impossible to calculate an accurate and appropriate dose of 
enrofloxacin for therapy since there is no information about the MIC. In addition, our 
study showed that most isolates interpreted as susceptible by disk diffusion showed MICs 
higher than 0.5 μg/mL on microdilution testing. For such isolates even a maximum dose 
of enrofloxacin would not be sufficient and could lead to therapeutic failure. Furthermore, 
the results of microdilution testing showed that only eight (8.9%) strains were susceptible 
to enrofloxacin, with six of them having a MIC of 0.5 μg/mL. These results suggest that 
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in most cases of P. aeruginosa infections enrofloxacin should be used at its maximum 
dose. In Croatia, enrofloxacin is licensed for veterinary use under several trade names, 
with a recommended dose of 2.5 to 5 mg/kg body weight in dogs. There is no additional 
data about the possibility of increasing the dose to 20 mg/kg for treating P. aeruginosa 
infections. We assume that most clinicians comply with the dosage guidelines in drug 
labels. this led us to the question about the validity of reporting P. aeruginosa strains as 
susceptible based on disk diffusion testing, and emphasizes the need for reviewing drug 
labels for enrofloxacin in Croatia, regarding dosage and duration of therapy.
Compared to this study, a lower susceptibility rate was reported in Croatia a few years 
ago (MEKIĆ et al., 2011) with one (1.1%) strain susceptible to enrofloxacin. In that study 
susceptibility testing was performed by etest®. Besides the difference in the methods used, 
there is a difference between the origins of the isolates. Isolates included in the study from 
2011 were all collected from the ears of dogs with otitis externa, and it is well known 
that otic isolates tend to show higher resistance rates to several antimicrobials, including 
enrofloxacin and other fluoroquinolones (PETERSEN et al., 2002; WILDERMUTH et al., 
2007; HARADA et al., 2012). Nevertheless, the sensitivity rate to enrofloxacin found in this 
study was still lower than sensitivity rates observed in other studies, where susceptibility 
ranged between 16% and 51% (COLOMBINI et al., 2000; MARTIN BARRASA et al., 2000; 
McKAY et al., 2007; WERCKENTHIN et al., 2007). 
On the other hand, the resistance to marbofloxacin found in this study is lower than 
the resistance rates of between 25% and 49% recorded in other studies (McKAY et al., 
2007; RUBIN et al, 2008; MÜLLER and HOM, 2009). the main reason for this is probably 
the fact that marbofloxacin is registered in Croatia only for topical treatment of otitis 
externa. On the other hand, enrofloxacin is registered for systemic use, and is prescribed 
not only for otitis externa but also for infections of other body sites. therefore, obviously, 
enrofloxacin is used more often than marbofloxacin. 
Resistance to ciprofloxacin has not significantly changed since the first study was 
conducted in Croatia in 2002, when 93.4% of isolates were susceptible and 3.8% were 
resistant to ciprofloxacin (ŠEOL et al., 2002). the resistance rate reported in the Croatian 
study from 2011 (MEKIĆ et al., 2011) was higher (8.7%) but the main reason for that 
was the difference in the origin of the isolates. a similar difference in susceptibility to 
ciprofloxacin between isolates of different origin had already been reported by PeterSeN 
et al. (2002). they detected 95.2% of skin isolates and 92.9% of ear isolates that were 
susceptible to ciprofloxacin. 
In the present study, all the isolates that were resistant to ciprofloxacin were also resistant 
to enrofloxacin and marbofloxacin, and there were significantly more ciprofloxacin-
susceptible strains than those susceptible to enrofloxacin and/or marbofloxacin. These 
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findings were expected and are in agreement with the results of other studies (RIDDLE et 
al., 2000; TEJEDOR et al., 2003; MEKIĆ et al., 2011).
In conclusion, comparison of the two methods showed that disk diffusion testing is not 
a method of choice for testing the susceptibility of P. aeruginosa isolates to enrofloxacin. 
Moreover, due to the high percentage of resistant and intermediately susceptible isolates, 
with MICs above 0.5 μg/mL, enrofloxacin is not a good choice for treating P. aeruginosa 
infections. For such isolates even the maximum recommended dose of enrofloxacin 
would not be high enough to achieve appropriate tissue levels (COLE et al., 2008). On the 
basis of the results obtained we consider marbofloxacin and ciprofloxacin as the drugs 
of choice among fluoroquinolones against P. aeruginosa. In the light of all of the above, 
our results emphasize the need for the revision of drug labels for enrofloxacin in Croatia. 
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SažetaK
Pseudomonas aeruginosa značajan je uzročnik velikog broja različitih infekcija u ljudi i životinja koje je 
teško liječiti zbog visokog stupnja urođene rezistencije ove bakterije. Također, vrsta P. aeruginosa vrlo brzo 
razvija nove mehanizme rezistencije, a više njih se može istovremeno očitovati u samo jednom izolatu što 
rezultira multirezistentnim fenotipom. Uzimajući u obzir to da na selekciju rezistentnih sojeva utječe pretjerana 
i neodgovarajuća uporaba antibiotika, osobito fluorokinolona, cilj ovog rada bio je istražiti osjetljivost izolata 
bakterije P. aeruginosa na pojedine fluorokinolone. Disk-difuzijskim i mikrodilucijskim postupkom određena 
je osjetljivost 90 sojeva izdvojenih iz pasa. Na temelju rezultata obiju metoda, izolati su bili značajno osjetljiviji 
na ciprofloksacin nego na marbofloksacin ili enrofloksacin i značajno osjetljiviji na marbofloksacin nego na 
enrofloksacin. Usporedbom ovih dviju metoda, uočeno je da su se rezultati dobiveni za ciprofloksacin podudarali 
kod 98,9% izolata, a za marbofloksacin kod 91,1% izolata. U podudarnosti interpretacijskih skupina dobivenih 
za ta dva antibiotika nije bilo statistički značajnih razlika. Rezultati dviju metoda za enrofloksacin bili su jednaki 
kod 76,6% izolata, a među metodama utvrđena je statistički značajna razlika za ovaj antibiotik (P<0,05). Većina 
„malih grešaka“ (16 od 20) rezultat je procjene testiranih izolata osjetljivim temeljem rezultata disk-difuzijske 
metode, a isti izolati testirani mikrodilucijom bili su umjereno osjetljivi. Takvi rezultati upućuju na zaključak da 
terapija enrofloksacinom temeljena samo na rezultatu disk-difuzijske metode može biti neučinkovita i kao takva 
može pridonijeti selekciji rezistentnih i multirezistentnih sojeva.
Ključne riječi: Pseudomonas aeruginosa, pas, fluorokinoloni, rezistencija, disk-difuzijski postupak, 
mikrodilucija________________________________________________________________________________________
